EA201891990A1 - Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна - Google Patents

Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна

Info

Publication number
EA201891990A1
EA201891990A1 EA201891990A EA201891990A EA201891990A1 EA 201891990 A1 EA201891990 A1 EA 201891990A1 EA 201891990 A EA201891990 A EA 201891990A EA 201891990 A EA201891990 A EA 201891990A EA 201891990 A1 EA201891990 A1 EA 201891990A1
Authority
EA
Eurasian Patent Office
Prior art keywords
muscular dystrophy
treatment
recombinant
follystatin
dyushen
Prior art date
Application number
EA201891990A
Other languages
English (en)
Russian (ru)
Inventor
Андреа Искендерян
Ангела У. Нортон
Чуань Шэнь
Кларк Пан
Original Assignee
Шайр Хьюман Дженетик Терапиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шайр Хьюман Дженетик Терапиз, Инк. filed Critical Шайр Хьюман Дженетик Терапиз, Инк.
Publication of EA201891990A1 publication Critical patent/EA201891990A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • C07K14/4708—Duchenne dystrophy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
EA201891990A 2016-03-04 2017-03-03 Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна EA201891990A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662303954P 2016-03-04 2016-03-04
PCT/US2017/020723 WO2017152090A2 (en) 2016-03-04 2017-03-03 Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
EA201891990A1 true EA201891990A1 (ru) 2019-04-30

Family

ID=58358939

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891990A EA201891990A1 (ru) 2016-03-04 2017-03-03 Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна

Country Status (14)

Country Link
US (1) US20200247856A1 (enExample)
EP (1) EP3423479A2 (enExample)
JP (1) JP2019509735A (enExample)
KR (1) KR20180137487A (enExample)
CN (1) CN109153708A (enExample)
AU (1) AU2017228475A1 (enExample)
BR (1) BR112018067747A2 (enExample)
CA (1) CA3016576A1 (enExample)
EA (1) EA201891990A1 (enExample)
IL (1) IL261397A (enExample)
MA (1) MA43588A (enExample)
MX (1) MX2018010470A (enExample)
SG (1) SG11201807400TA (enExample)
WO (1) WO2017152090A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020519291A (ja) * 2017-05-12 2020-07-02 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 組み換えフォリスタチン−ｆｃ融合タンパク質およびデュシェンヌ型筋ジストロフィーの治療における使用
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
CN108303860B (zh) * 2018-03-26 2019-11-08 西安电子科技大学 一种用于无掩模光刻扫描的分布式曝光方法
WO2019191204A1 (en) * 2018-03-28 2019-10-03 Acceleron Pharma Inc. Follistatin polypeptides for the treatment of muscle contracture
WO2020160118A1 (en) 2019-01-29 2020-08-06 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
AU2023291634C9 (en) 2022-06-15 2026-01-22 UCB Biopharma SRL Follistatin fusion proteins
KR20250036807A (ko) 2022-06-15 2025-03-14 유씨비 바이오파마 에스알엘 신장 질환의 예방, 치료 또는 완화를 위한 융합 단백질

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4336498B2 (ja) 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
BR0307907A2 (pt) * 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
HK1209034A1 (en) * 2012-06-21 2016-03-24 Indiana University Research And Technology Corporation Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
EP3626735A1 (en) * 2012-12-18 2020-03-25 Novartis AG Stabilized insulin-like growth factor polypeptides
EA201590719A1 (ru) * 2013-01-25 2015-12-30 Шир Хьюман Дженетик Терапис, Инк. Фоллистатин в лечении мышечной дистрофии дюшенна
WO2014187807A1 (en) * 2013-05-21 2014-11-27 Arcarios B.V. Follistatin derivatives
KR102132144B1 (ko) * 2014-06-04 2020-07-09 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물

Also Published As

Publication number Publication date
CN109153708A (zh) 2019-01-04
WO2017152090A2 (en) 2017-09-08
EP3423479A2 (en) 2019-01-09
MX2018010470A (es) 2018-12-06
AU2017228475A1 (en) 2018-09-13
IL261397A (en) 2018-10-31
US20200247856A1 (en) 2020-08-06
KR20180137487A (ko) 2018-12-27
MA43588A (fr) 2021-06-02
JP2019509735A (ja) 2019-04-11
SG11201807400TA (en) 2018-09-27
BR112018067747A2 (pt) 2019-01-08
WO2017152090A3 (en) 2017-10-19
CA3016576A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
EA201590719A1 (ru) Фоллистатин в лечении мышечной дистрофии дюшенна
CY1123925T1 (el) Μια νεα μορφη il33, μεταλλαγμενες μορφες της il33, αντισωματα, δοκιμασιες και μεθοδοι χρησης των ιδιων
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
PE20170665A1 (es) Anticuerpos anti-tau humanizados
MX2018010470A (es) Proteinas de fusion folistatina-fc recombinantes y su uso en el tratamiento de la distrofia muscular de duchenne.
MX2019013523A (es) Proteínas de fusión de folistatina-fc recombinante y uso en el tratamiento de la distrofia muscular de duchenne.
MY196095A (en) Antibody That Binds to Envelope Glycoprotein of Severe Fever With Thrombocytopenia Syndrome Virus and use for Same
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MA40801B2 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA38498B1 (fr) Protéines de liaison anti-lag-3
EA201790192A1 (ru) СПОСОБ СНИЖЕНИЯ Fc-РЕЦЕПТОРНОГО СВЯЗЫВАНИЯ МОЛЕКУЛ СЫВОРОТОЧНОГО IgG У СУБЪЕКТА
MX386491B (es) Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn.
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
EA202092420A1 (ru) Антитело против pd-l1 и его применение
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX2015009690A (es) Anticuerpos anti-flt-1 para tratar la distrofia muscular de duchenne.
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
CR20200642A (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiples
MX2017012828A (es) Anticuerpos anti-flt-1 para el tratamiento de distrofia muscular de duchenne.
EA201990253A1 (ru) Гуманизированные антитела против s100a9 и их применение
EA201692495A8 (ru) Биспецифические антитела к il4-il13
EA201892231A1 (ru) Способ очистки белка
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
MX2022004164A (es) Anticuerpos anti-flt-1 para tratar displasia broncopulmonar.